Nov 6 - Moderna lifted its full-year revenue forecast on Friday, after strong international demand for its COVID-19 vaccine and payments from partnerships helped the biotech swing to profit in the third quarter.

The strong results provide fresh momentum for Moderna’s efforts to build a sustainable business through new products, including its newly approved flu vaccine and a personalized cancer vaccine candidate, which investors see as key to the long-term growth of its mRNA platform.

Moderna now expects total revenue to grow 15% to 25% in 2026, above its previous forecast of up to 10% growth.

The US FDA cleared Moderna’s flu vaccine, mFlusiva, in August for adults aged 50 and older, marking the first authorization of an mRNA-based seasonal influenza shot.

Moderna said it plans a limited US launch during the 2026-27 flu season because the approval came after flu vaccine contracts for the year were wrapped up.

Moderna and partner Merck said last month that their personalized cancer vaccine, intismeran autogene, combined with Merck’s blockbuster immunotherapy Keytruda cut the risk of melanoma recurrence or death by 42% in a large trial, potentially paving the way for a new era of cancer treatment. The companies anticipate commercial launch of the treatment in 2027.

Moderna shares have surged more than eight-fold this year, mostly after announcing the trial success of intismeran autogene in August, making them one of the best performers in the S&P 500.

The company reported third-quarter revenue of $1.3 billion, topping analysts’ average estimate of $885.1 million, according to data compiled by LSEG.

Moderna earned a net profit of $162 million, compared with a net loss of about $200 million a year earlier. Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.

Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.

It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the s or advertisers.